Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study we evaluated the analytical and clinical performances of the HepB Typer-Entecavir kit (GeneMatrix, Korea) in detecting entecavir-resistance-associated mutations. Methods: The HepB Typer-Entecavir kit was evaluated for its limit of detection, interference, cross-reactivity, and precision using HBV reference standards made by diluting high-titer viral stocks in HBV-negative human serum. The performance of the HepB Typer-Entecavir kit for detecting mutations related to entecavir resistance was compared with direct sequencing for 396 clinical samples from 108 patients. Results: Using the reference standards, the detection limit of the HepB Typer-Entecavir kit was found to be as low as 500 copies/mL. No cross-reactivity was observed, and elevated levels of various interfering substances did not adversely affect its analytical performance. The precision test conducted by repetitive analysis of 2,400 replicates with reference standards at various concentrations showed 99.9% agreement (2398/2400). The overall concordance rate between the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical samples was 99.5%. Conclusions: The HepB Typer-Entecavir kit showed high reliability and precision, and comparable sensitivity and specificity for detecting mutant virus populations in reference and clinical samples in comparison with direct sequencing. Therefore, this assay would be clinically useful in the diagnosis of entecavir-resistance-associated mutations in chronic hepatitis B. (Clin Mol Hepatol 2013;19:399-408)
Abstract
Background/Aims: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study we evaluated the analytical and clinical performances of the HepB Typer-Entecavir kit (GeneMatrix, Korea) in detecting entecavir-resistance-associated mutations. Methods: The HepB Typer-Entecavir kit was evaluated for its limit of detection, interference, cross-reactivity, and precision using HBV reference standards made by diluting high-titer viral stocks in HBV-negative human serum. The performance of the HepB Typer-Entecavir kit for detecting mutations related to entecavir resistance was compared with direct sequencing for 396 clinical samples from 108 patients. Results: Using the reference standards, the detection limit of the HepB Typer-Entecavir kit was found to be as low as 500 copies/mL. No cross-reactivity was observed, and elevated levels of various interfering substances did not adversely affect its analytical performance. The precision test conducted by repetitive analysis of 2,400 replicates with reference standards at various concentrations showed 99.9% agreement (2398/2400). The overall concordance rate between the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical samples was 99.5%. Conclusions: The HepB Typer-Entecavir kit showed high reliability and precision, and comparable sensitivity and specificity for detecting mutant virus populations in reference and clinical samples in comparison with direct sequencing. Therefore, this assay would be clinically useful in the diagnosis of entecavir-resistance-associated mutations in chronic hepatitis B. (Clin Mol Hepatol 2013;19:399-408)
참고문헌 (40)
- Lai CL, "Viral hepatitis B", Lancet, 362, pp.2089~2094 (2003)
- Di Bisceglie AM, "Hepatitis B and hepatocellular carcinoma", Hepatology, 49(Suppl), pp.S56~S60 (2009)
- Lavanchy D, "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- Chan HL, "Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma", J Clin Microbiol, 47, pp.1830~1836 (2009)
- Mendy ME, "Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa", J Viral Hepat, 17, pp.115~122 (2010)
- Van Damme P, "Strategies for global prevention of hepatitis B virus infection", Adv Exp Med Biol, 659, pp.175~188 (2010)
- Keeffe EB, "Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B", Clin Gastroenterol Hepatol, 5, pp.890~897 (2007)
- Ghany M, "Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B", Gastroenterology, 132, pp.1574~1585 (2007)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Chang TT, "A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients", Gastroenterology, 129, pp.1198~1209 (2005)
- Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Sherman M, "Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B", Gastroenterology, 130, pp.2039~2049 (2006)
- Suzuki F, "Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients", J Gastroenterol Hepatol, 23, pp.1320~1326 (2008)
- Yao G, "Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China", Hepatol Int, 1, pp.365~372 (2007)
- Schiff E, "Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis", Am J Gastroenterol, 103, pp.2776~2783 (2008)
- Schiff ER, "Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 9, pp.274~276 (2011)
- Villeneuve JP, "Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient", J Hepatol, 39, pp.1085~1089 (2003)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Park JW, "Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance", J Viral Hepat, 18, pp.e475~e481 (2011)
- Hong SP, "Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments", J Hepatol, 40, pp.837~844 (2004)
- Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
- Innaimo SF, "Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus", Antimicrob Agents Chemother, 41, pp.1444~1448 (1997)
- Zoulim F, "Entecavir: a new treatment option for chronic hepatitis B", J Clin Virol, 36, pp.8~12 (2006)
- Cheong JY, "Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B", Hepatogastroenterology, 55, pp.1029~1033 (2008)
- Hong SP, "High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry", Nat Protoc, 3, pp.1476~1484 (2008)
- Kim HS, "Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization", Antivir Ther, 10, pp.441~449 (2005)
- Kim YJ, "Population genotyping of hepatitis C virus by matrix-assisted laser desorption", ionization time-of-flight mass spectrometry analysis of short DNA fragments, 2005, pp.51, 1123~1131
- Lee CH, "Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough", Gastroenterology, 130, pp.1144~1152 (2006)
- Oh HB, "Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5’ untranslated region using a matrix assisted laser desorption", ionization time of flight-based assay, restriction fragment mass polymorphism, 2008, pp.80, 1712~1719
- Paik YH, "The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B", Antivir Ther, 11, pp.447~455 (2006)
- Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
- Sauer S, "Single-nucleotide polymorphisms: analysis by mass spectrometry", Nat Protoc, 1, pp.1761~1771 (2006)
- de Franchis R, "A potent inhibitor of Taq polymerase copurifies with human genomic DNA", Nucleic Acids Res, 16, pp.10355~ (1988)
- Beutler E, "Interference of heparin with the polymerase chain reaction", Biotechniques, 9, pp.166~ (1990)
- Heo J, "A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine", Antivir Ther, 17, pp.1563~1570 (2012)
- 김병욱, "만성 B형간염 환자에서 엔테카비어 투여 후 발생한 유전자형 내성", Clinical and Molecular Hepatology, 16(2), pp.147~157 (2010), 대한간학회
- Woo HY, "Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients", Antivir Ther, 12, pp.7~13 (2007)
- Van Laethem K, "Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations", J Acquir Immune Defic Syndr, 22, pp.107~118 (1999)